Lv11
50 积分 2024-11-24 加入
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
5小时前
待确认
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study
2个月前
已完结
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial
3个月前
已完结
中国高血压急症诊治规范
3个月前
已完结
卵巢浆液性癌的两级分级系统及其临床意义
4个月前
已完结
Histopathologic Grading of Ovarian Carcinoma: A Review and Proposal
4个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
4个月前
已完结
Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights
4个月前
已关闭
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
4个月前
已完结
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
